Regeneron Pharmaceuticals is acquiring "substantially all" of 23andMe's assets for $256 million following a bankruptcy auction. The drugmaker is buying 23andMe's Personal Genome Service, Total ...

Regeneron Pharmaceuticals on Monday announced plans to purchase genetic testing company 23andMe for $256 million. The New York-based drugmaker is set to take over 23andMe after winning a ...

Biotechnology leader Regeneron Pharmaceuticals is acquiring genetic testing firm 23andMe for $256 million following its bankruptcy filing. The deal excludes 23andMe’s telehealth subsidiary ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy.

Regeneron bids for 23andMe at a discounted price of $256 million. The testing firm was once valued at $3.5 billion.

23andMe, a once high-flying genetic testing company, filed for for Chapter 11 bankruptcy protection in March. Regeneron Pharmaceuticals on Monday announced it will acquire "substantially all" of ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. The proposed transaction ...

Regeneron Pharmaceuticals on Monday announced it will acquire "substantially all" of 23andMe's assets for $256 million. Stream NBC4 newscasts for free right here, right now.

Regeneron will be keeping all of 23andMe’s employees, Jensen added. As part of the court-supervised sale process, 23andMe required all bidders to guarantee that they will comply with its privacy ...

Regeneron will be keeping all of 23andMe’s employees, Jensen added. As part of the court-supervised sale process, 23andMe required all bidders to guarantee that they will comply with its privacy ...